Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
KPTI
KPTI
Nasdaq
Health Technology
Pharmaceuticals: Major
6.98
USD
-0.2
-2.79%
Açık: 07-23 14:45 (UTC+0)

KPTI Temel İstatistikler

YÜKSEK
7.16
Açık
7.14
Hacim
149.18K
Düşük
6.88
Önceki Kapanış
7.18
İşlem Değeri
1.04M
52H En Yüksek
10.99
Göreceli Hacim
0.229
Dalgalanma (%)
3.83%
52H En Düşük
3.65
Devir Oranı
0.66%
Piyasa Değeri
162.71M
F/K (TTM)
--
F/K (Yıllık)
--
GD/DD
-0.61
F/S
1.08
Hisse Başına Kazanç (EPS)
-15.087
Temettü (TTM)
0
Temettü Verimi
0.00%
Dolaşımdaki hisseler
22.66M
Para Birimi
USD

KPTI Fiyat Performansı

7 gün
30 gün
90 gün
180 gün
Yıl başından bugüne
1 Yıl
KPTI Para Akışı Dağılımı
KPTI Günlük Açığa Satış Hacmi
KPTI Short Interest Geçmişi
As of 2026-07-23, the Karyopharm Therapeutics Inc. (KPTI) stock price today is 6.98. Based on this price, the company has a market capitalization of $162.71M, with a P/E ratio of --. On 2026-07-23, KPTI traded between 6.88 and 7.16. Today’s stock price is 1.45% above the daily low and 2.51% below the daily high, placing KPTI alt aralıkta its most recent trading range. Trading volume currently stands at 149.18K, compared with an average daily volume of 652.80K. This suggests that trading activity is olağan seviyesinin belirgin şekilde altında than usual. Over the past year, Karyopharm Therapeutics Inc. shares have traded between 3.65 and 10.99. At today’s price, KPTI is 91.23% above its 52-week low and 36.49% below its 52-week high.
Şirket adı
Karyopharm Therapeutics Inc.
Sektör
Health Technology
Endüstri
Pharmaceuticals: Major
Borsalar
Nasdaq
Çalışan Sayısı
228
Lot Büyüklüğü
100
Resmî web sitesi
Para Birimi
USD
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

KPTI FAQ

Ara
Daha fazla